PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment.
Robert B KargboPublished in: ACS medicinal chemistry letters (2023)
The anti-apoptotic BCL-2 protein family members, including BCL-2, BCL-XL, and MCL-1, have been established as promising therapeutic targets for cancer treatment, as evidenced by the FDA approval of venetoclax in 2016. Researchers have redoubled their efforts to design analogs that exhibit enhanced pharmacokinetic and pharmacodynamic characteristics. This Patent Highlight features PROTAC compounds that demonstrate potent and selective BCL-2 degradation, with potential applications in the treatment of cancer, autoimmune disorders, and immune system diseases.
Keyphrases
- cell death
- papillary thyroid
- multiple sclerosis
- molecular docking
- anti inflammatory
- big data
- deep learning
- amino acid
- chronic lymphocytic leukemia
- artificial intelligence
- drug induced
- climate change
- binding protein
- risk assessment
- replacement therapy
- molecular dynamics simulations
- lymph node metastasis
- protein protein